Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study
about
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysiA safety evaluation of raltegravir for the treatment of HIV.Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings.Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women.Adult antiretroviral therapy guidelines 2017.Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and researchAssessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
P2860
Q38791126-A7FFBE20-5585-4EBE-BC3C-568F3E48628EQ38860427-7FF4EE1B-2226-4BC7-A3B0-EDDD8F1A4F76Q40507125-AA89DF1E-9540-4604-8A39-CACD205B9C4BQ45323778-BB0506BF-8854-4D55-B3B6-D79E17407F71Q47130269-A41AA86B-02A3-4FD2-B4AB-05CE0A43F8F9Q47258937-4DA09C65-3DC2-4A34-AA55-97AE2A35CF37Q47377203-6BA91048-8CD9-46FA-9E3B-6E0298415383Q47554851-E4C27839-0BE2-40C9-BC5B-89F8678E56BDQ47563310-36607D66-DF16-4FDD-9545-036E5E2049F9Q52641448-3CDAED63-1378-4A84-9CB2-F9E9ACAB919DQ53694767-4F99A8A1-6127-43D9-8438-77BBEBB94FB3Q58038937-B1350559-C46B-4851-940B-0E1215B1E08AQ58780819-80B7A117-1762-46CE-8F6A-D7DF5A85B24F
P2860
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Raltegravir in second-line ant ...... phase 3, non-inferiority study
@en
Raltegravir in second-line ant ...... hase 3, non-inferiority study.
@nl
type
label
Raltegravir in second-line ant ...... phase 3, non-inferiority study
@en
Raltegravir in second-line ant ...... hase 3, non-inferiority study.
@nl
prefLabel
Raltegravir in second-line ant ...... phase 3, non-inferiority study
@en
Raltegravir in second-line ant ...... hase 3, non-inferiority study.
@nl
P2093
P2860
P1433
P1476
Raltegravir in second-line ant ...... phase 3, non-inferiority study
@en
P2093
ACTG A5273 Study Group
Alberto M La Rosa
Ann C Collier
Bernadette Jarocki
Carole L Wallis
John W Mellors
Linda J Harrison
Mina C Hosseinipour
P2860
P304
P356
10.1016/S2352-3018(16)30011-X
P577
2016-04-18T00:00:00Z